25th Annual Meeting of the Society of Urologic Oncology - TCAF Meet & Greet Social

On December 5, Testicular Cancer Awareness Foundation (TCAF) hosted a Meet and Greet social sponsored by Fennec Pharmaceuticals during the 25th annual meeting of the Society of Urologic Oncology (SUO) in Dallas, Texas. 56 people attended this private gathering, including some of the top testicular cancer surgeons in North America.

Events like this help bring together testicular cancer medical experts to not only socialize, but to also share important information on the research they are conducting and various “tips of the trade.” Connections made between experts will help shape the future of the care and treatment of testicular cancer.

This was also a great opportunity to congratulate Clint Cary, MD, MPH, MBA on his newly appointed position as chair of urology at IU.

For TCAF, hosting an event like this provides an opportunity to teach the experts about the resources and programs offered for patients and their families. Together, we are making a positive, impactful difference in the fight against testicular cancer.

TCAF is incredibly grateful for the continued support of Fennec Pharmaceuticals, most recently being the presenting sponsor of the 2024 Testicular Cancer Conference.

Fennec offers the first and only FDA approved hearing loss prevention for adolescents and young adults (AYA) who receive cisplatin chemotherapy to help reduce ototoxicity (hearing loss). Fennec’s hearing loss drug, Pedmark, is also recommended by the NCCN guidelines for patients 15-39 years of age. If you are about to start treatment for testicular cancer that includes cisplatin chemotherapy, contact Fennec HEARS at 1-833-7PEDMARK or 1-(833)-773-3627.

Look for TCAF’s booth at future urology and oncology gatherings.